ProMIS Neurosciences Inc. Files 8-K

TL;DR

ProMIS Neurosciences Inc. updated its address and confirmed its name change history in a new 8-K filing.

AI Summary

On December 12, 2025, ProMIS Neurosciences Inc. filed an 8-K report. The filing indicates that the company's principal executive offices are located at Suite 200, 1920 Yonge Street, Toronto, Ontario, M4S 3E2. The company was formerly known as AMORFIX LIFE SCIENCES LTD until August 31, 2006.

Why It Matters

This filing provides updated corporate information and confirms the company's current operational address and former name, which is standard for regulatory compliance.

Risk Assessment

Risk Level: low — This filing is a routine corporate update and does not contain any new material financial or operational information that would significantly alter the company's risk profile.

Key Players & Entities

• ProMIS Neurosciences Inc. (company) — Registrant
• AMORFIX LIFE SCIENCES LTD (company) — Former company name
• December 12, 2025 (date) — Date of earliest event reported
• Suite 200, 1920 Yonge Street, Toronto, Ontario, M4S 3E2 (address) — Principal executive offices

FAQ

Key Financial Figures

• $1.00 m — ompany has regained compliance with the $1.00 minimum bid price requirement for continu
• $1.00 — mon stock was trading below the minimum $1.00 per share requirement for continued inc

Filing Documents

• pmn-20251212x8k.htm (8-K) — 32KB
• 0001104659-25-121627.txt ( ) — 152KB
• pmn-20251212.xsd (EX-101.SCH) — 3KB
• pmn-20251212_def.xml (EX-101.DEF) — 3KB
• pmn-20251212_lab.xml (EX-101.LAB) — 17KB
• pmn-20251212_pre.xml (EX-101.PRE) — 12KB
• pmn-20251212x8k_htm.xml (XML) — 5KB

01 Other Events

Item 8.01 Other Events. On December 12, 2025, ProMIS Neurosciences Inc. (the "Company") received a written notification from the Nasdaq Stock Market Listing Qualifications Staff indicating that the Company has regained compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market ("Nasdaq") pursuant to NASDAQ Listing Rule 5550(a)(2) ("Bid Price Rule") and that the matter is now closed. As previously disclosed, on January 8, 2025, the Company received a deficiency letter from Nasdaq notifying the Company that, for the 30 consecutive business days prior to the date of the deficiency letter, the closing bid price for the Company's common stock was trading below the minimum $1.00 per share requirement for continued inclusion on Nasdaq pursuant tothe Bid Price Rule. In accordance with Nasdaq rules, the Company was provided with an initial period of 180 calendar days, or until July 2, 2025, to regain compliance with the Bid Price Rule. Subsequently, the Company was granted an additional 180-day grace period, until December 29, 2025, to regain compliance with the Bid Price Rule. Nasdaq's determination was based on the Company meeting the continued listing requirement for stockholder's equity and all other initial listing standards for Nasdaq with the exception of the Bid Price Rule, and the Company's provided written notice of its confirmation to cure the deficiency during the additional compliance period, including by effecting a reverse stock split, if necessary. The closing bid price of the Company's common shares has been $1.00 or greater for the 10 consecutive business days from November 28, 2025 to December 11, 2025. Accordingly, the Company has regained compliance with the Bid Price Rule.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROMIS NEUROSCIENCES INC. Date: December 16, 2025 By: /s/ Neil Warma Name: Neil Warma Title: Chief Executive Officer